Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...
2don MSN
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target ...
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback